Anti-Depressant Feature: What the mhra says

THE MHRA says that in June 2003, it was the first regulatory body to advise that Seroxat should not be used in the treatment of children and adolescents with depressive illness. It said this was because of lack of evidence of effectiveness and an increas

THE MHRA says that in June 2003, it was the first regulatory body to advise that Seroxat should not be used in the treatment of children and adolescents with depressive illness.

It said this was because of lack of evidence of effectiveness and an increased risk of suicidal behaviour in this group.

The MHRA has advised that though there is a slight increase in the risk of suicide in patients taking SSRIs compared to those taking a placebo, the risk is no higher in SSRIs than in other anti-depressants.

It says young adults are at a higher background risk of suicidal behaviour than older adults so young adults treated with SSRIs should be closely monitored.